Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Number of clinical trials in Finland falls in 2007

This article was originally published in Scrip

Executive Summary

The number of clinical trials conducted in Finland last year fell to 459 from above 500 in 2006, which was an “exceptionally high” number, says Pharma Industry Finland, the national association. One quarter (115) of them involved medicines for CNS disorders, followed by 104 trials for cancer and substances modulating the immune system response. 175 new trials were initiated in 2007 which was nearly an average figure. The number of patients enrolled increased by around 20% to 48,000, with half of them taking part in Phase III trials and almost 40% in Phase IV trials. The majority (80%) were involved in vaccine trials. In the six years to 2007, clinical trials of vaccines prevailed over other products, with seven to 19 studies being conducted in this group every year. Children participated in those of rotavirus, varicella, influenza and human papillomavirus vaccines.

You may also be interested in...



Poland's new law fixes prices and trade mark-ups of reimbursed drugs

Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.

Global pharma boosts business in Russia - Why Russia (introduction)

In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.

Russia's president Medvedev wants talks on trials mutual recognition with US and EU

Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.

Topics

UsernamePublicRestriction

Register

LL1130096

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel